IRLAB’s drug candidate mesdopetam's mechanism of action receives confirmation by independent scientists
IRLAB (Nasdaq Stockholm: IRLAB A) announced today that independent scientists have confirmed that the dopamine D3 receptor (D3R) is a highly promising drug target with therapeutic potential in levodopa-induced dyskinesia, especially when the receptor’s unique signaling properties are taken into account. IRLAB’s mesdopetam is currently the most advanced D3R antagonist compound in the global neurology pipeline. It is used in the scientific article to exemplify a compound that could have an impact on the management of anumber of disorders marked by aberrant D3R activity. The article was